Cancer Archives

circulating tumor cells, cancer, clinical trials

News and Trends 28 Jul 2022

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […]

July 28, 2022 - 3 minutesmins - By Liza Laws

In Depth 28 Jul 2022

How can vaccines keep up with evolving Covid-19 variants?

Vaccines for COVID-19 have saved lives all over the world, but their protection is threatened by the rise of variants of concern. Companies are developing ways to combat the evolving virus, such as booster shots and universal coronavirus vaccines. During 2021, a plethora of COVID-19 vaccines was rolled out around the world. Since then, mass […]

July 28, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 27 Jul 2022

Diffusion Pharmaceuticals to start brain tumor clinical trial

U.S. biopharma company Diffusion Pharmaceuticals Inc. is set to start a new phase 2 clinical trial. Entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (GBM) Patients when Administered with Standard of Care (“SOC”),” the company said the trial is a result of a collaboration with the United States […]

July 27, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jul 2022

SOTIO Biotech starts solid tumor trial

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors. The company has dosed its first patient in the AURELIO-04 combination trial of SOT101 and MSD’s (Merck & Co., Inc., Rahway, NJ) anti-PD-1 therapy KEYTRUDA (pembrolizumab). “The initiation of this phase […]

July 27, 2022 - 3 minutesmins - By Jim Cornall

In Depth 27 Jul 2022

The race to uncloak cancer with liquid biopsies

Until recently, cancer detection depended on invasive solid tissue sampling that didn’t provide a complete picture. An emerging crowd of biotechs is making it easier to detect and monitor cancer with liquid biopsies. The notion that a person’s blood can reveal a wealth of health information looked so shiny that the infamous blood diagnostics company […]

July 27, 2022 - 10 minutesmins - By Editorial Team

News and Trends 26 Jul 2022

Pleco Therapeutics expands into U.S. and names president

Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

cancer shutterstock immunotherapy deep science ventures

News and Trends 26 Jul 2022

Deep Science Ventures deepens CRUK pact to co-found oncology startups

The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK’s innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K. Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration […]

July 26, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 26 Jul 2022

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […]

July 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Jul 2022

Positive results for drug combination used to treat rare blood cancer

Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […]

July 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Jul 2022

Trial for drug targeting cancerous tumors begins in China

A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […]

July 18, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors

How can vaccines keep up with evolving Covid-19 variants?

Diffusion Pharmaceuticals to start brain tumor clinical trial

SOTIO Biotech starts solid tumor trial

The race to uncloak cancer with liquid biopsies

Pleco Therapeutics expands into U.S. and names president

Deep Science Ventures deepens CRUK pact to co-found oncology startups

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Almirall launches new call to find innovative therapies for skin diseases

Positive results for drug combination used to treat rare blood cancer

Trial for drug targeting cancerous tumors begins in China

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!